|
The affected products with field complaints alleging pe-pur foam degradation have undergone the establishment of complaint codes specifically identifying foam degradation, for the c series.A field correction action(2021-06-a) was initiated, and medical device recall letters were issued.A field action was initiated to replace pe-pur foam in affected products; degradation was added to the respective dfmeas and the risk management file¿ er 2205744 v11(yoda risk matrix) was updated to include hazards associated with foam degradation based on complaints analyzed through various health hazard evaluations (hhes).Risk tags ¿ vduri005, vdtox001 reflect the safety risk assessment of design containing the affected pe-pur foam.These complaints were monitored and trended in accordance with the complaint trending procedures.If the complaints were determined to meet the criteria for escalation, they were escalated for risk assessment through the post market clinical escalation process.As of the date of submission for this report, there is no indication that complaints for the failure in question have led to unacceptable levels of severity or probabilities of harm, and therefore no further action will be pursued.The purpose of a device history record (dhr) review is to confirm that the device was manufactured in compliance with all established specifications.The reportable malfunction of foam degradation has been investigated extensively and is recorded under capa 7211.A device being manufactured out of specifications is not related to the root cause of foam degradation.Therefore a review of the device history record (dhr) is not required and will not be conducted.
|